These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24560878)

  • 1. Rheumatoid arthritis quality measures and radiographic progression.
    Desai SP; Liu CC; Tory H; Norton T; Frits M; Lillegraven S; Weinblatt M; Coblyn J; Yazdany J; Shadick N; Solomon DH
    Semin Arthritis Rheum; 2014 Aug; 44(1):9-13. PubMed ID: 24560878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.
    Li W; Sasso EH; van der Helm-van Mil AH; Huizinga TW
    Rheumatology (Oxford); 2016 Feb; 55(2):357-66. PubMed ID: 26385370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression.
    Ellingsen T; Hansen I; Thorsen J; Møller BK; Tarp U; Lottenburger T; Andersen LS; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Lindegaard H; Jacobsen S; Østergaard M; Vestergaard A; Jurik AG; Junker P; Christensen AF; Hetland ML; Hørslev-Petersen K; Stengaard-Pedersen K
    Scand J Rheumatol; 2014; 43(2):91-100. PubMed ID: 23980529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Radiographic Outcomes in Patients Diagnosed with Early Rheumatoid Arthritis in the First Years of the Biologic Treatment Era: A 10-year Prospective Observational Study.
    Haugeberg G; Bøyesen P; Helgetveit K; Prøven A
    J Rheumatol; 2015 Dec; 42(12):2279-87. PubMed ID: 26568592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.
    Brahe CH; Østergaard M; Johansen JS; Defranoux N; Wang X; Bolce R; Sasso EH; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Lottenburger T; Ammitzbøll C; Jørgensen A; Krintel SB; Raun J; Hetland ML
    Scand J Rheumatol; 2019 Jan; 48(1):9-16. PubMed ID: 29985080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
    JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort.
    Mueller RB; Kaegi T; Finckh A; Haile SR; Schulze-Koops H; von Kempis J;
    Rheumatology (Oxford); 2014 Apr; 53(4):671-7. PubMed ID: 24352338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
    Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
    Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.
    Lillegraven S; Prince FH; Shadick NA; Bykerk VP; Lu B; Frits ML; Iannaccone CK; Kvien TK; Haavardsholm EA; Weinblatt ME; Solomon DH
    Ann Rheum Dis; 2012 May; 71(5):681-6. PubMed ID: 21994234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.
    Ornbjerg LM; Ostergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Ringsdal VS; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Dencker D; Hansen A; Andersen AR; Hetland ML
    Ann Rheum Dis; 2013 Jan; 72(1):57-63. PubMed ID: 22532636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study.
    Ometto F; Raffeiner B; Bernardi L; Bostsios C; Veronese N; Punzi L; Doria A
    Arthritis Res Ther; 2016 Apr; 18():89. PubMed ID: 27080123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    Ten Klooster PM; Versteeg LGA; Oude Voshaar MAH; de la Torre I; De Leonardis F; Fakhouri W; Zaremba-Pechmann L; van de Laar M
    Arthritis Res Ther; 2019 Nov; 21(1):237. PubMed ID: 31718678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis.
    Nair SC; Bijlsma JW; van der Werf JH; van der Veen MJ; Linn-Rasker SP; Vreugdenhil S; Lafeber FP; Welsing PM
    J Rheumatol; 2013 Sep; 40(9):1505-12. PubMed ID: 23818710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
    Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
    Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML
    Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
    Bouman CAM; van der Maas A; van Herwaarden N; Sasso EH; van den Hoogen FHJ; den Broeder AA
    Rheumatology (Oxford); 2017 Jun; 56(6):973-980. PubMed ID: 28339738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.